Reported Saturday, Nuvation Bio Revealed Findings From The Crucial Phase 2 TRUST-I Trial Of Their Experimental ROS1 Inhibitor, Taletrectinib At The ASCO 2024
Reported Saturday, Nuvation Bio Revealed Findings From The Crucial Phase 2 TRUST-I Trial Of Their Experimental ROS1 Inhibitor, Taletrectinib At The ASCO 2024
Nuvation Bio在ASCO 2024上报告，他们实验性的ROS1抑制剂Taletrectinib在关键的2期TRUST-I试验中发现了结果。
- Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study
- Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at two years
- TRUST-I is one of two registrational Phase 2 studies evaluating taletrectinib for the treatment of patients with advanced ROS1-positive NSCLC
- 在进行研究的未接受ROS1酪氨酸激酶抑制剂（TKI）的进展期ROS1阳性非小细胞肺癌患者中，91%的人使用爱文思控股治疗后肿瘤萎缩，而在先前接受ROS1 TKI治疗的患者中占52%。
- 持久的治疗效果得到长期随访的证实；71%的未接受TKI治疗的患者在两年后仍没有进展。
- TRUST-I是进行注册的两个II期研究，评估taletrectinib用于治疗进展期ROS1阳性非小细胞肺癌患者之一。